Immune pneumonia or enterocolitis has not been observed in patients treated with envafolimab, and it is possibly related to the functional reserve between PD-1 and programmed death ligand 2.[28,29] With excellent structural stability, low molecular weight, and strong tissue penetration, envafolimab antibodies represent a potential advancement in therapy as they can be easily administered subcutaneously; moreover, monodomain antibodies lacking immunoglobulin light chains are a possible alternative to full monoclonal antibodies. Here, PDCD1 is linked to enterocolitis.